Home>Topics>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb BMY

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. Goldman: Time to buy volatility

      Headlines

      Wed, 17 Sep 2014

      Katherine Fogertey. "In recent years, October volatility has been even higher and even more of a standout." Bristol - Myers Squibb (NYSE: BMY ), Dish Network (NASDAQ: DISH ), Intel (NASDAQ: INTC ), Ford (NYSE: F ), J.C. Penney (NYSE

    2. Bristol Myers Squibb declares $0.36 dividend

      Headlines

      Tue, 16 Sep 2014

      Bristol - Myers Squibb (NYSE: BMY ) declares $0.36/share quarterly dividend , in line with previous. Forward yield 2.82% Payable Nov. 3; for shareholders of record Oct. 3; ex-div Oct. 1. Post your comment!

    3. New Diabetes Drugs Gain Approval - Florins Versus Oral Insulin

      Headlines

      Sun, 14 Sep 2014

      side effect profile that rivals medications like Bristol - Myers Squibb 's (NYSE: BMY ) anti-blood clot drug Plavix which has caused ..... infection of the penis. Farxiga, a product of Bristol -Meyers Squibb and Complete Story »

    4. New Morningstar Analyst Report for Gilead Sciences Inc

      Stock Reports

      Thu, 11 Sep 2014

      2021, and hepatitis C regimens from Bristol and AbbVie could spark price wars if ..... initiatives. Martin, who was previously Bristol - Myers ' director of antiviral chemistry and ..... sees strong competition from firms like Bristol and AbbVie, or if pharmacy benefit managers

    5. New Morningstar Analyst Report for Amgen Inc

      Stock Reports

      Thu, 11 Sep 2014

      Novartis' Reclast and cheaper generic bisphosphonates; Vectibix competes with Roche's Avastin and Eli Lilly and Bristol - Myers Squibb 's Erbitux. If Kyprolis fails in head-to-head studies against leading proteasome inhibitor Velcade, Amgen

    6. Bristol-Myers Squibb's ( BMY ) Management Presents At Morgan Stanley Healthcare Conference (Transcript)

      Headlines

      Mon, 8 Sep 2014

      By SA Transcripts : Bristol - Myers Squibb Company (NYSE: BMY ) Morgan Stanley Healthcare ..... the next session here with Bristol - Myers . Please note that we need ..... Chief Operating Officer for Bristol . He originally joined the

    7. Bristol - Myers sues Merck over U.S. immunotherapy patent

      Headlines

      Fri, 5 Sep 2014

      Sept 5 (Reuters) - Bristol - Myers Squibb Co on Thursday filed a lawsuit against Merck & Co Inc for allegedly infringing its immunotherapy patent. The company is seeking unspecified damages.

    8. Teva launches generic Baraclude in U.S.

      Headlines

      Thu, 4 Sep 2014

      Teva Pharmaceutical Industries ( TEVA -0.2% ) launches its generic equivalent to Bristol - Myers Squibb 's ( BMY +0.2% ) Baraclude ( entecavir ) Tablets, 0.5 mg and 1 mg, in the U.S. Teva was first to file its ANDA so it has 180

    9. New Morningstar Analyst Report for Bristol-Myers Squibb Company

      Stock Reports

      Thu, 4 Sep 2014

      believe a large portion of Bristol 's current valuation ..... clinical data are poor. Bristol carries a high price ..... upcoming patent losses. Bristol 's growth prospects ..... reinvestment in the business. Bristol - Myers Squibb discovers, develops

    10. Alder BioPharma regains rights to drug candidates from Bristol - Myers

      Headlines

      Tue, 2 Sep 2014

      to its rheumatoid arthritis drug candidate clazakizumab and its migraine prevention candidate ADL403 from Bristol - Myers Squibb (NYSE: BMY ) due to its focus on other therapeutic areas. Clazakizumab is an IL-6 inhibitor which plays a key role

    « Prev12345Next »
    Content Partners